Primary prevention with a defibrillator: are therapies always really optimized before implantation?

Left ventricle ejection fraction (LVEF) ≤ 30-35% is widely accepted as a cut-off for primary prevention with an implantable cardiac defibrillator (ICD) in patients with both ischaemic and non-ischaemic cardiomyopathy supposedly on optimal medical therapy. This study reports evolutions of LVEF and tr...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Europace (London, England) England), 2012-11, Vol.14 (11), p.1572-1577
Hauptverfasser:	Foucault, Anthony, Amelot, Mathieu, Gomes, Sophie, Champ-Rigot, Laure, Saloux, Eric, Pellissier, Arnaud, Labombarda, Fabien, Scanu, Patrice, Milliez, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenergic beta-Antagonists - therapeutic use Adult Aged Angiotensin II Type 1 Receptor Blockers - therapeutic use Angiotensin-Converting Enzyme Inhibitors - therapeutic use Cardiomyopathies - complications Cardiomyopathies - physiopathology Cardiomyopathies - therapy Cardiovascular Agents - therapeutic use Chi-Square Distribution Death, Sudden, Cardiac - etiology Death, Sudden, Cardiac - prevention & control Defibrillators, Implantable - adverse effects Electric Countershock - adverse effects Female France Humans Life Sciences Male Middle Aged Primary Prevention - instrumentation Primary Prevention - methods Recovery of Function Retrospective Studies Risk Factors Stroke Volume - drug effects Time Factors Treatment Outcome Ventricular Dysfunction, Left - etiology Ventricular Dysfunction, Left - physiopathology Ventricular Dysfunction, Left - therapy Ventricular Function, Left - drug effects
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!